Regado Biosciences Inc (RGDO) 5.68 $RGDO
Regado Biosciences Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri May 09, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the Compensation Committee of Regado's Board of Directors granted an inducement award pursuant to NASDAQ Listing Rule 5635(c)(4) to R. Don Elsey in connection with his employment as Regado's Senior Vice President, Finance, and Chief Financial Officer.
Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary
Regado Biosciences to Provide First Quarter 2014 Financial Results and Corporate Highlights
PR Newswire - Wed May 07, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will hold a conference call and live audio webcast on Wednesday, May 14, 2014, at 8:30 a.m. EDT to discuss its first quarter 2014 financial results and corporate highlights.
Regado Biosciences Appoints R. Don Elsey Chief Financial Officer
PR Newswire - Thu May 01, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of R. Don Elsey as Senior Vice President, Finance, and Chief Financial Officer. Mr. Elsey will be responsible for leading Regado's financial strategy and operations along with its financial reporting and controls activities.
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Regado Biosciences Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Apr 16, 8:35AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced underwritten public offering. The gross proceeds to Regado from its sale of 10,000,000 shares of common stock at a price to the public of $6.00 per share were approximately $60.0 million, prior to deducting underwriting discounts and commissions and other offering expenses payable by Regado.
This Week's 5 Dumbest Stock Moves
Rick Munarriz, The Motley Fool - Motley Fool - Fri Apr 11, 3:45PM CDT
Stupidity is contagious -- even respectable companies can catch it. As we do every week, let's take a look at five dumb financial events this week that may make your head spin. 1. Dis a Pier Sometimes it's hard to herd scapegoats. Pier 1...
Why Regado Biosciences (RGDO) Stock Is Down Today
at The Street - Fri Apr 11, 9:37AM CDT
Regado Biosciences (RGDO) plunged on Friday after the biopharmaceutical company priced an offering of its common stock. The company priced 10 million shares at $6 a share. The offering should close on or about April 16 and includes a 30-day option...
Regado Biosciences Announces Pricing of Public Offering of Common Stock
PR Newswire - Fri Apr 11, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $6.00 per share to the public. The gross proceeds to Regado from this offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Regado. The offering is expected to close on or about April 16, 2014, subject to the satisfaction of customary closing conditions. Regado has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Regado expects to use the net proceeds of this offering to fund further clinical development of its lead product candidate, REG1, and for working capital and other general corporate purposes.
Regado Biosciences to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
PR Newswire - Thu Mar 20, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 21st Annual Future Leaders in the Biotech Industry Conference taking place on March 28, 2014, at the Millennium Broadway Hotel & Conference Center in New York City.
Regado Biosciences Announces Year-End 2013 Financial Results and Corporate Highlights
PR Newswire - Wed Mar 12, 4:35PM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. A conference call and webcast to discuss the results will be held March 13 at 8:30 a.m. EDT.
Regado Rises on REG1 Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 1:16PM CDT
Shares of Regado soared 38.1% and also touched a 52-week high.
3 Stocks Making Health-Care Investors Big Money Today
David Williamson, The Motley Fool - Motley Fool - Mon Mar 10, 5:57PM CDT
Despite an overall down day on the market today, the health-care sector emerged looking pretty good, with a handful of big winners. In this video, Motley Fool health-care analyst David Williamson looks at three top performers. Regado Biosciences ...
Regado Biosciences Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri May 09, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the Compensation Committee of Regado's Board of Directors granted an inducement award pursuant to NASDAQ Listing Rule 5635(c)(4) to R. Don Elsey in connection with his employment as Regado's Senior Vice President, Finance, and Chief Financial Officer.
Acute Coronary Syndrome - Pipeline Review, H1 2014: 21 Companies and 29 Drugs Profiled
M2 - Wed May 07, 12:15PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2f56rx/acute_coronary) has announced the addition of the "Acute Coronary Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - Ampio Pharmaceuticals, Inc. - Arena Pharmaceuticals, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Auspex Pharmaceuticals, Inc. - Bayer AG - CSL Limited - GlaxoSmithKline plc - LG Life Sciences, Ltd. - Lacer, S.A. - Lee's Pharmaceutical Holdings Limited - Ligand Pharmaceuticals, Inc. - MedImmune, LLC - Medicure Inc. - Pfizer Inc. - Regado Biosciences, Inc. - Stealth Peptides Inc. - The Medicines Company - Viron Therapeutics, Inc. - Vitae Pharmaceuticals, Inc. - XOMA Corporation Drug Profiles: - cangrelor - rivaroxaban - BAY-818781 - REG-1 - clopidogrel bisulfate - VT-111a - CSL-112 - gevokizumab - losmapimod - MTP-131 - ZK-001 - PR-15 - temanogrel hydrochloride - MDCO-216 - losmapimod - LC-231306 - ACP-501 - PF-06282999 - Artpep-2 - DMI-4983 - LA-8045 - COR-3 - COR-2 - AEM-28 - Type 5 Adenylyl Cyclase Inhibitors - tirofiban hydrochloride transdermal - Liver X Receptor Modulator For Acute Coronary Syndrome - Anti Platelet Program - SD-970 For more information visit http://www.researchandmarkets.com/research/2f...e_coronary
Regado Biosciences to Provide First Quarter 2014 Financial Results and Corporate Highlights
PR Newswire - Wed May 07, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will hold a conference call and live audio webcast on Wednesday, May 14, 2014, at 8:30 a.m. EDT to discuss its first quarter 2014 financial results and corporate highlights.
Regado Biosciences Appoints R. Don Elsey Chief Financial Officer
PR Newswire - Thu May 01, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced the appointment of R. Don Elsey as Senior Vice President, Finance, and Chief Financial Officer. Mr. Elsey will be responsible for leading Regado's financial strategy and operations along with its financial reporting and controls activities.
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Regado Biosciences Announces Closing of Public Offering of Common Stock
PR Newswire - Wed Apr 16, 8:35AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced underwritten public offering. The gross proceeds to Regado from its sale of 10,000,000 shares of common stock at a price to the public of $6.00 per share were approximately $60.0 million, prior to deducting underwriting discounts and commissions and other offering expenses payable by Regado.
This Week's 5 Dumbest Stock Moves
Rick Munarriz, The Motley Fool - Motley Fool - Fri Apr 11, 3:45PM CDT
Stupidity is contagious -- even respectable companies can catch it. As we do every week, let's take a look at five dumb financial events this week that may make your head spin. 1. Dis a Pier Sometimes it's hard to herd scapegoats. Pier 1...
Why Regado Biosciences (RGDO) Stock Is Down Today
at The Street - Fri Apr 11, 9:37AM CDT
Regado Biosciences (RGDO) plunged on Friday after the biopharmaceutical company priced an offering of its common stock. The company priced 10 million shares at $6 a share. The offering should close on or about April 16 and includes a 30-day option...
Regado Biosciences Announces Pricing of Public Offering of Common Stock
PR Newswire - Fri Apr 11, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $6.00 per share to the public. The gross proceeds to Regado from this offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Regado. The offering is expected to close on or about April 16, 2014, subject to the satisfaction of customary closing conditions. Regado has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Regado expects to use the net proceeds of this offering to fund further clinical development of its lead product candidate, REG1, and for working capital and other general corporate purposes.
Regado Biosciences to Present at the 21st Annual Future Leaders in the Biotech Industry Conference
PR Newswire - Thu Mar 20, 6:30AM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 21st Annual Future Leaders in the Biotech Industry Conference taking place on March 28, 2014, at the Millennium Broadway Hotel & Conference Center in New York City.
Regado Biosciences Announces Year-End 2013 Financial Results and Corporate Highlights
PR Newswire - Wed Mar 12, 4:35PM CDT
Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. A conference call and webcast to discuss the results will be held March 13 at 8:30 a.m. EDT.
Regado Rises on REG1 Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 1:16PM CDT
Shares of Regado soared 38.1% and also touched a 52-week high.
3 Stocks Making Health-Care Investors Big Money Today
David Williamson, The Motley Fool - Motley Fool - Mon Mar 10, 5:57PM CDT
Despite an overall down day on the market today, the health-care sector emerged looking pretty good, with a handful of big winners. In this video, Motley Fool health-care analyst David Williamson looks at three top performers. Regado Biosciences ...
